Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease JACC State-of-the-Art Review

Cecilia R. Varga, John G.F. Cleland, William T. Abraham, Gregory Y.H. Lip, Francisco Leyva, Parta Hatamizadeh*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Heart failure and chronic kidney disease are common and clinically important conditions that regularly coexist. Electrophysiologic changes of advanced heart failure often result in abnormal conduction, causing dyssynchronous contraction, and development of ventricular arrhythmias, which can lead to sudden cardiac arrest. In the last 2 decades, implantable cardioverter-defibrillator and cardiac resynchronization therapy devices have been developed to address these complications. However, when the coexisting chronic kidney disease is advanced, the associated pathophysiologic cardiovascular changes can alter the efficacy and safety of those interventions and complicate the management. This review explores the impact of comorbid advanced heart failure and advanced chronic kidney disease on the efficacy and safety of implantable cardioverter-defibrillator and cardiac resynchronization therapy, the currently available evidence, and potential future directions.
Original languageEnglish
Pages (from-to)1342-1362
Number of pages21
JournalJournal of the American College of Cardiology
Volume84
Issue number14
Early online date23 Sept 2024
DOIs
Publication statusPublished - 1 Oct 2024

Keywords

  • arrhythmia
  • cardiac dyssynchrony
  • cardiorenal syndrome
  • heart failure
  • nephrocardiology
  • sudden cardiac arrest

Fingerprint

Dive into the research topics of 'Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease JACC State-of-the-Art Review'. Together they form a unique fingerprint.

Cite this